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Background. The safetyandtolerabilityofregadenoson,apharmacologicstressagent thatis
excreted primarily bythekidneys,wereexaminedinsubjectswithchronickidney disease (CKD).
Methods. This multicenter, double-blind, randomized, placebo-controlled study involved
men and women, ‡18 years of age, with stage 3 or 4 [estimated glomerular ﬁltration rate (eGFR)
30-59 mL/minute/1.73 m
2 and 15-29 mL/minute/1.73 m
2, respectively] CKD and known or sus-
pected coronary artery disease. Subjects were randomized 2:1 to receive one 10-second
intravenous injection of regadenoson 0.4 mg or placebo. The primary outcome measure was the
frequency of serious adverse events over 24-h post-dose.
Results. The study included 432 subjects with stage 3 (regadenoson n 5 287; placebo
n 5 145) and 72 with stage 4 (regadenoson n 5 47; placebo n 5 25) CKD. No serious adverse
events or deaths were reported over 24-h post-dose. The overall adverse event incidence was
higherwithregadenosonthanplacebo(62.6%vs21.2%;P < .0001).Ofthemostcommonadverse
events (‡5%) reported by subjects receiving regadenoson, headache (24.9% vs 7.1%), dyspnea
(19.2% vs 0.6%), chest discomfort (14.7% vs 0.6%), nausea (14.7% vs 1.2%), ﬂushing (12.0% vs
1.8%), and dizziness (9.6% vs 0.6%) occurred signiﬁcantly more often (P < .0001) with regade-
noson than placebo. There were no trends for clinically meaningful changes in eGFR from
baseline to 24-h post-dose in subjects with stage 3 or 4 CKD.
Conclusions. Regadenoson was not associated with any serious or unexpected adverse events
in subjects with stage 3 or 4 CKD. (J Nucl Cardiol 2012;19:319–29.)
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INTRODUCTION
Single-photon emission computed tomography
(SPECT) stress imaging is widely used in the clinical
assessment of patients with known or suspected coronary
artery disease (CAD). Although exercise stress is the
preferred modality, many patients are unable to exercise
sufﬁciently because of age and physical limitations.
Pharmacologic stress agents, such as adenosine and
dipyridamole, are commonly used as effective substitutes
for exercise stress in the diagnosis and prognosis of CAD
intheseindividuals.Adenosineanddipyridamolearenon-
selective adenosine agonist stress agents which induce
coronary hyperemia directly or indirectly via adenosine
2A (A2A) cell membrane G-protein-coupled receptors
found in abundance on arteriolar smooth muscle cells.
However, they also act on other adenosine receptor
subtypes, such as A1,A 2B, and A3 adenosine receptors,
causing frequent clinically important side effects (e.g.,
atrioventricular block, peripheral vasodilation, and bron-
choconstriction) as well as other less serious side
effects.
1-3 Logically, one may assume that a pharmaco-
logic stress agent that selectively targets the A2A receptor
would provide adequate coronary vasodilatation for
SPECT and lessen or avoid otherundesirableside effects.
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319Regadenoson is a selective A2A receptor agonist
that was approved for use as a pharmacologic stressor
for SPECT by the US Food and Drug Administration in
April 2008.
4-11 The afﬁnity of regadenoson for adeno-
sine A2A receptors is 9-fold greater than for adenosine
A1 receptors, and it has a very low afﬁnity for A2B and
A3 receptors.
5 Regadenoson has a triphasic half-life. The
half-life of the initial phase is 2-4 minutes and coincides
with the period of maximal coronary hyperemia; the
second phase is 15-30 minutes and is not associated with
a pharmacodynamic effect, as evidenced by resolution
of side effects; and the terminal half-life is approxi-
mately 2 h. The extended terminal half-life is not
considered clinically signiﬁcant, as accumulation is not
a risk following administration of a single intravenous
(IV) bolus dose.
12
A signiﬁcant proportion of patients referred for
pharmacologic stress SPECT are elderly.
13 Many of
these individuals are likely to have chronic kidney
disease (CKD). This results from the gradual decline in
GFR with age of approximately 0.4 mL/minute/year and
the prevalence of comorbidities, such as diabetes and
hypertension, that are associated with the development
of CKD.
14-16 Thus, it is important to assess the safety
and tolerability of regadenoson in this population.
Although regadenoson was safe and well tolerated in 2
pivotal, Phase 3 clinical trials involving over 1,200
patients undergoing SPECT myocardial perfusion imag-
ing (MPI),
17,18 individuals with renal impairment were
excluded from these trials.
The objective of this study was to examine the
safety and tolerability of a single IV dose (0.4 mg/5 mL)
of regadenoson in subjects with stage 3 or 4 CKD. A
placebo group was included to characterize adverse
event rates in an untreated population.
METHODS
Study Participants
Participants in this study were men and women outpa-
tients, C18 years of age, with stage 3 or 4 CKD at screening.
Estimated glomerular ﬁltration rate (eGFR) was calculated
from the serum creatinine concentration using the Modiﬁcation
of Diet in Renal Disease (MDRD) equation
19,20 and was used
to stage each subject’s level of CKD according to the National
Kidney Foundation classiﬁcation.
21 Stage 3 CKD was deﬁned
as eGFR 30-59 mL/minute/1.73 m
2 and stage 4 as eGFR
15-29 mL/minute/1.73 m
2. Subjects also had diagnosed CAD
or C2 of the following CAD risk factors: type 2 diabetes,
hypertension, hypercholesterolemia, current or history of
cigarette smoking (minimum 10 pack-years exposure), or
obesity (body mass index[30 kg/m
2). Subjects had no speciﬁc
indication for cardiac imaging.
Subjects were excluded if they had other clinically
signiﬁcant illnesses (e.g., neurologic, gastrointestinal, renal,
hepatic, cardiovascular, metabolic, endocrine, hematologic, or
psychiatric disorders), medical conditions, or laboratory
abnormalities within 2 weeks prior to screening that, in the
investigator’s judgment, might interfere with study assess-
ments; second- or third-degree heart block or sinus node
dysfunction in the absence of a functioning pacemaker;
symptomatic hypotension; allergy or intolerance to aminoph-
ylline or regadenoson and its excipients; or a hemoglobin level
B9 g/dL. Also excluded were women who were pregnant,
lactating, or of childbearing potential and not using contra-
ception, subjects who were participating in another clinical
trial or had received an investigational drug in the 30 days
prior to screening, and those who had undergone surgery in the
previous 3 months. Subjects with asthma or chronic obstruc-
tive pulmonary disease were not excluded from the trial.
However, no formal criteria were included in the protocol to
speciﬁcally capture whether subjects had these coexisting
conditions.
Study Design and Treatments
This Phase 4, double-blind, randomized, placebo-con-
trolled, parallel-group clinical trial was conducted at 32 sites in
the United States (ClinicalTrials.gov number, NCT00863707).
The ﬁrst participant was enrolled in April 2009 and the study
was completed (last subject last visit) in December 2009. The
study was conducted in compliance with the principles of the
International Conference on Harmonization (ICH) of Techni-
cal Requirements for Registration of Pharmaceuticals for
Human Use and Good Clinical Practice. The protocol was
approved by the Institutional Review Board/Independent
Ethics Committee of each study center. Each participant
signed a written informed consent form prior to any study-
related procedures.
Following a screening visit, eligible subjects returned to
the clinic within 3 weeks and were randomized to double-blind
treatment with either regadenoson 0.4 mg/5 mL or matching
placebo using a 2:1 (regadenoson:placebo) computer-gener-
ated randomization schedule prepared by the sponsor prior to
study initiation. The study drug was administered as a single
IV bolus injection over 10 seconds, followed immediately by a
5 mL 0.9% sodium chloride USP (saline) ﬂush. If necessary,
aminophylline was given in doses ranging from 50 to 250 mg
by slow IV injection (50-100 mg over 30-60 seconds) to
attenuate severe and/or persistent adverse reactions. Subjects
were monitored in the clinic for 8-h post-dose; clinically stable
subjects were then discharged. The follow-up visit was
conducted 24 ± 4 h after study drug administration.
Subjects were required to abstain from eating and
drinking for 30 minutes before and after dosing, and from
smoking for 3 h before to 8 h after dosing. Foods and
beverages containing methylxanthines (i.e., caffeine, theobro-
mine, or theophylline) and medications containing
theophylline were prohibited from 12 h before study drug
administration to the follow-up visit. Dipyridamole was
withheld for at least 2 days prior to dosing.
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Adverse events (coded using Medical Dictionary for
Regulatory Activities [MedDRA] version 11.1 terms) were
collected from the time of study drug administration to the
follow-up visit and were assessed by the investigator for
severity and causal relationship to the study drug. An adverse
event was deﬁned as any unfavorable and unintended sign
(including an abnormal laboratory ﬁnding), symptom or
disease temporally associated with the use of a study drug,
whether or not it was related to the study drug. All adverse
events occurring during the study were followed up until
resolved or judged to be no longer clinically signiﬁcant, or
until they became chronic to the extent that they could be fully
characterized. The primary outcome measure was the fre-
quency of serious adverse events. In accordance with the ICH
of Technical Requirements for Registration of Pharmaceuticals
for Human Use and Good Clinical Practice, serious adverse
events were deﬁned as any adverse event that (i) results in
death, persistent, or signiﬁcant disability or incapacity; (ii)
consists of a congenital anomaly or birth defect; (iii) requires
inpatient hospitalization or prolongation of hospitalization; (iv)
is life-threatening; or (v) is considered medically important.
Vital signs [systolic blood pressure (SBP), diastolic blood
pressure (DBP), heart rate (HR), and respiratory rate] and 12-
lead electrocardiograms (ECGs) were assessed at screening, at
baseline (prior to study drug administration), at 5, 15, and
30 minutes and 1, 2, 3-7, and 8 h after regadenoson or placebo
administration and at the follow-up visit, 24 ± 4 h later. The
proportion of subjects meeting each of the following prespec-
iﬁed vital sign criteria was also determined:
– HR increase of[40 beats per minute (bpm)
– SBP\90 mm Hg
– SBP decrease of[35 mm Hg
– SBP C200 mm Hg
– SBP increase of C50 mm Hg
– SBP C180 mm Hg and increase of C20 mm Hg from
baseline
– DBP\50 mm Hg
– DBP decrease of[25 mm Hg
– DBP C115 mm Hg
– DBP increase of C30 mm Hg.
Continuous 12-lead ECG monitoring and pulse oximetry
began 2 h before study drug administration and continued until
2-h post-dose. Pulse oximetry was also conducted at 3-7 and
8 h after drug administration. Additional evaluations con-
ducted at screening, baseline, and follow-up included serum
chemistry (sodium, potassium, blood urea nitrogen, bicarbon-
ate, calcium, phosphate, chloride, glucose, and creatinine);
kidney function, using the MDRD equation to calculate eGFR
from serum creatinine;
19 hemoglobin level; and physical
examination.
Statistical Analyses
A total of 450 subjects enrolled with 300 receiving
regadenoson was considered appropriate clinically to assess
the safety and tolerability of the drug. This sample size was
deemed sufﬁcient to detect an adverse event rate of 54 per
10,000 subjects with approximately 80% probability and an
adverse event rate of 76 per 10,000 subjects with approxi-
mately 90% probability. Safety analyses were conducted on all
randomized subjects who received any amount of study drug.
Protocol Amendments
Protocol amendments of note that were made after trial
commencement included the addition of current or history of
cigarette smoking (minimum 10 pack-years exposure) as a
qualifying CAD risk factor and an update of the race
component of the MDRD equation used to calculate eGFR.
Both of these amendments were introduced after the enroll-
ment of 17 regadenoson and 11 placebo subjects.
RESULTS
Subject Characteristics
Of 511 subjects randomized, 504 received study
drug and were included in the safety analysis (3 subjects
randomized to regadenoson and 4 randomized to pla-
cebo did not receive study drug; Figure 1). This safety
analysis set comprised 432 subjects with stage 3 CKD
(regadenoson n = 287; placebo n = 145) and 72 with
stage 4 CKD (regadenoson n = 47; placebo n = 25).
No signiﬁcant differences were observed between the
regadenoson and placebo groups in demographic or
baseline clinical characteristics (Table 1). The 2 treat-
ment groups were also comparable with regard to
therapies used during the 21 days prior to study drug
administration and those used from the time of study
drug administration to the follow-up visit.
Serious Adverse Events
No serious adverse events, including deaths, were
reported with regadenoson or placebo from the time of
study drug administration to the follow-up visit at 24 h
(primary outcome measure). One subject died during a
cardiopulmonary arrest 20 days after receiving placebo;
this event was considered unrelated to the study drug by
the investigator.
All Adverse Events
The overall incidence of adverse events was signif-
icantly higher with regadenoson than placebo: adverse
events were reported by 62.6% (209/334) subjects
receiving regadenoson and 21.2% (36/170) receiving
placebo (P\.0001). None of the adverse events resulted
in study discontinuation. Table 2 lists the adverse events
that occurred in C5% of subjects in the regadenoson
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nausea, ﬂushing, and dizziness were signiﬁcantly more
common with regadenoson than placebo (P\.0001).
Adverse events considered possibly or probably related to
study medication by the investigator were also more
common with regadenoson (202/334 subjects; 60.5%)
than placebo (29/170 subjects; 17.1%) (P\.0001).
Most adverse events were mild. However, 7 severe
adverse events (i.e., resulted in an inability to perform
daily activities) were reported in 5 (1.5%) regadenoson
subjects (headache, n = 2; dyspnea, n = 2; nausea,
n = 1; sensation of heaviness, n = 1; neck pain, n = 1).
None of the placebo subjects experienced severe adverse
events. The majority of adverse events occurred within
2 h of study drug administration: 204/334 (61.1%)
subjects receiving regadenoson and 25/170 (14.7%)
receiving placebo had adverse events during this period.
The stage of CKD did not affect adverse event rates
for either study drug. Adverse events occurred in 182/
287 (63.4%) of regadenoson-treated subjects with stage
3 and 27/47 (57.4%) with stage 4 CKD, and in 30/145
(20.7%) of placebo-treated subjects with stage 3 and 6/
25 (24.0%) with stage 4 CKD. These rates were similar
to the overall incidence for each treatment group.
Five adverse events were considered clinically
important. Hemiparesis occurred in a 67-year-old white
male with a history of CKD, prior myocardial infarction
with stent placement, hypercholesterolemia, hyperten-
sion, hypothyroidism, right facial numbness, and sleep
apnea. His concomitant medications included aspirin,
levothyroxine, atorvastatin, lisinopril, omega-3 fatty
acids, fenoﬁbric acid, and ezetimibe. The subject expe-
rienced transient left-sided weakness starting 2 minutes
after the administration of regadenoson and lasting
for 28 minutes. Blood pressure was 92/58 mm Hg at
baseline (prior to regadenoson administration), 100/
58 mm Hg at 5 minutes post-dose, and 98/70 mm Hg at
30 minutes post-dose, when the hemiparesis resolved.
Pulse oximetry showed that his oxygen saturation, which
was 97% at 1 minute pre-dose, decreased to 86% at 5
minutes post-dose, but recovered to 94% at 10 minutes
post-dose. The subject recovered fully, required no
treatment, and had no sequelae. The event was deemed
possibly related to the study drug by the investigator.
Another subject (a 73-year-old white male with a
history of CKD, cigarette smoking, hypercholesterol-
emia, hypertension, obesity, and CAD) experienced non-
sustained ventricular tachycardia 2 h after regadenoson
Assessed for eligibility 
(n=767)
Randomized (n=511)
Excluded (n=256)
Reasons:
did not fulfill eligibility criteria (n=189)
withdrew consent (n=29)
enrollment closed (n=19)
lost to follow-up (n=4)
other reasons (n=15)
Matching placebo 5 mL IV bolus (n=174)
Received study drug (n=170)
Did not receive study drug (n=4)
had stage 2 CKD (n=3)
had elevated blood pressure and
bradycardia on day of dosing (n=1)
Regadenoson 0.4 mg/5 mL IV bolus (n=337)
Received study drug (n=334)
Did not receive study drug (n=3)
withdrew consent (n=1)
atrial fibrillation on day of dosing (n=1)
unable to obtain IV access (n=1)
Analyzed (n=334) 
(safety analysis set)
Lost to follow-up (n=0) Lost to follow-up (n=0)
Analyzed (n=170) 
(safety analysis set)
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Figure 1. Subject disposition.
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as part of the continuous Holter monitor data and was
recorded as an adverse event of\1 minute in duration.
Concomitant medications included desloratadine, meto-
prolol, rabeprazole, atorvastatin, doxazosin, potassium,
furosemide, warfarin, fenoﬁbrate, and levothyroxine.
His blood pressure remained stable throughout the
procedure, being 128/70 mm Hg at baseline and 122/
80 mm Hg 2 h after regadenoson administration, when
the episode of ventricular tachycardia occurred. This
event was considered to be mild in severity, not related
to study drug, and required no treatment.
Non-sustained ventricular tachycardia also was
reported in a placebo subject after discharge (22-h
post-dose). This was a single episode, which was
considered mild and possibly related to study drug
(placebo). No adverse events were reported in this
subject following documentation of the arrhythmia.
Second-degree atrioventricular node block occurred in
a placebo subject 60 minutes post-dose, and sinus arrest
of approximately 4 seconds occurred in a placebo
subject 13 minutes post-dose.
One subject in the regadenoson group received
25 mg of aminophylline orally to attenuate dyspnea.
None of the placebo-treated subjects experienced any
adverse reactions that were sufﬁciently severe and/or
persistent to require either IV or oral aminophylline.
Serum Chemistry
Mean changes from baseline were numerically
small and similar with regadenoson and placebo for all
Table 1. Baseline demographics and clinical characteristics (safety analysis set*)
Regadenoson (n 5 334) Placebo (n 5 170) P value
Sex, n (%)
Male 184 (55.1) 92 (54.1) .85
Female 150 (44.9) 78 (45.9)
Ethnicity, n (%)
Non-Hispanic or Latino 296 (88.6) 147 (86.5) .474
Hispanic or Latino 38 (11.4) 23 (13.5)
Race, n (%)
White 254 (76.0) 115 (67.6) .085
Black/African American 68 (20.4) 47 (27.6)
Asian 10 (3.0) 6 (3.5)
Other 2 (0.6) 2 (1.2)
Age
Mean (SD) (years) 66.4 (11.3) 66.1 (10.9) .727
Age C65 years, n (%) 193 (57.8) 92 (54.1)
Weight (kg)
Mean (SD) 94.3 (24.6) 89.9 (23.0) .052
Body mass index (kg/m
2)
Mean (SD) 33.1 (7.3) 31.9 (7.2) .083
CKD, n (%)
 
Stage 3 287 (85.9) 145 (85.3) .893
Stage 4 47 (14.1) 25 (14.7)
CAD history and risk factors, n (%)
CAD
  133 (39.8) 76 (44.7) .494
Hypertension 321 (96.1) 161 (94.7) .493
Hypercholesterolemia
  278 (83.2) 145 (85.3) .742
Type 2 diabetes
  187 (56.0) 98 (57.6) .405
Obesity
  (BMI[30 kg/m
2) 218 (65.3) 98 (57.6) .054
Smoking
  (C10 pack-years) 139 (41.6) 67 (39.4) .697
* The safety analysis set includes all randomized subjects who received any amount of drug.
CAD, Coronary artery disease; CKD, chronic kidney disease; BMI, body mass index.
  Based on the National Kidney Foundation Practice Guidelines for Chronic Kidney Disease.
21 Stage 3 CKD was not subcate-
gorized as stage 3a (eGFR 45-59 mL/minute/1.73 m
2) or stage 3b (eGFR 30-44 mL/minute/1.73 m
2) CKD.
  Either ongoing or subject had a history of condition.
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Estimated Glomerular Filtration Rate
Mean eGFR at baseline was similar in the regad-
enoson and placebo groups for all subjects and for those
with either stage of CKD (Table 3). Mean changes from
baseline in eGFR, irrespective of CKD stage, were
numerically small and comparable in the placebo and
regadenoson groups (Table 3). Ten subjects (all with
stage 3 CKD) had a reduction in eGFR of [10 mL/
minute/1.73 m
2 from baseline: eGFR decreased by
11-12 mL/minute/1.73 m
2 in 2 placebo subjects with
no associated adverse events; eGFR decreased by
11-17 mL/minute/1.73 m
2 in 7 regadenoson subjects,
4 of whom experienced mild adverse events typical of
regadenoson; and eGFR decreased by 42 mL/minute/
1.73 m
2 (from 73 to 31 mL/minute/1.73 m
2) in 1 reg-
adenoson subject, without any associated adverse
events. A Fisher’s exact test showed that the number
of regadenoson and placebo subjects with a [10 mL/
minute/1.73 m
2 decrease in eGFR was not statistically
signiﬁcant, whether considering only subjects with stage
3 CKD (P = .5072) or all subjects (P = .5068).
Vital Signs and 12-Lead ECGs
Mean changes from baseline in SBP and DBP were
generally similar between the regadenoson and placebo
groups (Figure 2). However, HR increased to[100 bpm
in the 1-h post-dose period in more subjects receiving
Table 2. Adverse events occurring in C5% of subjects receiving regadenoson
Adverse
event, n
(%)
All subjects Stage 3 CKD Stage 4 CKD
Regadenoson
(n 5 334)
Placebo
(n 5 170)
Regadenoson
(n 5 287)
Placebo
(n 5 145)
Regadenoson
(n 5 47)
Placebo
(n 5 25)
Any adverse
event
209 (62.6) 36 (21.2)* 182 (63.4) 30 (20.7) 27 (57.4) 6 (24.0)
Headache 83 (24.9) 12 (7.1)* 70 (24.4) 11 (7.6) 13 (27.7) 1 (4.0)
Dyspnea 64 (19.2) 1 (0.6)* 54 (18.8) 1 (0.7) 10 (21.3) 0
Chest discomfort 49 (14.7) 1 (0.6)* 44 (15.3) 1 (0.7) 5 (10.6) 0
Nausea 49 (14.7) 2 (1.2)* 42 (14.6) 1 (0.7) 7 (14.9) 1 (4.0)
Flushing 40 (12.0) 3 (1.8)* 38 (13.2) 3 (2.1) 2 (4.3) 0
Dizziness 32 (9.6) 1 (0.6)* 30 (10.5) 1 (0.7) 2 (4.3) 0
Dysgeusia 18 (5.4) 6 (3.5) 14 (4.9) 4 (2.8) 4 (8.5) 2 (8.0)
*P\.0001 for regadenoson versus placebo (2-tailed Fisher’s exact test) for all subjects.
Table 3. Change from baseline to 24-h post-dose in eGFR
eGFR, mL/minute/1.73 m
2
Regadenoson Placebo
n Mean ± SD n Mean ± SD
All subjects
Baseline 330 41.96 ± 11.89 167 41.26 ± 11.27
Change from baseline 325 -0.43 ± 5.99 165 -0.34 ± 4.37
Stage 3 CKD
Baseline 284 44.69 ± 10.29 142 44.20 ± 9.06
Change from baseline 281 -0.60 ± 6.36 140 -0.46 ± 4.62
Stage 4 CKD
Baseline 46 25.09 ± 5.50 25 24.56 ± 7.34
Change from baseline 44 0.66 ± 2.47 25 0.32 ± 2.50
eGFR, Estimated glomerular ﬁltration rate; SD, standard deviation.
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[1.8%]) (P = .03). The percentages of subjects meeting
other prespeciﬁed vital sign criteria were comparable
between the regadenoson and the placebo groups.
Changes in respiratory rate were also similar between
the 2 groups.
Figure 2. Mean (±SD) SBP, DBP, and HR following the administration of regadenoson or
placebo.
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ity was similar in the regadenoson and placebo groups at
all the post-dose intervals assessed. No clinically mean-
ingful differences were observed between treatments in
the mean change from baseline in HR, QT interval
(including measurement using Bazett’s and Fridericia’s
corrections), PR interval, or QRS interval. Some differ-
ences were noted between the treatment groups at 5
minutes post-dose: mean HR increased from baseline
with regadenoson (13.9 bpm) but not placebo
(-0.4 bpm) and mean RR interval decreased from
baseline with regadenoson (-163.6 ms) but not placebo
(3.2 ms); these differences diminished at each succes-
sive post-dose interval. Continuous 12-lead ECG
monitoring showed no apparent differences in the
distribution of ECG abnormalities from baseline to 2-h
post-dose with either regadenoson or placebo.
Pulse Oximetry and Physical Examination
Findings
No statistically signiﬁcant differences were observed
between treatment groups in the mean change in oxygen
saturation from baseline to 2-h post-dose for subjects with
stage 3 (regadenoson -0.2% ± 1.6%; placebo -0.6% ±
2.7%) or stage 4 (regadenoson -0.4% ± 1.4%; placebo
-0.3% ±1.0%) CKD. The proportions of subjects in the
stages 3 and 4 CKD subgroups with oxygen saturation
\92%(consideredclinicallymeaningful)atanytimeduring
the 2-h continuous post-dose pulse oximetry collection
period were also similar with regadenoson and placebo:
188/276 (68.1%) of stage 3 CKD subjects receiving
regadenoson and 84/142 (59.2%) receiving placebo (dif-
ference -9.0%; 95% conﬁdence interval -18.7%, 0.8%),
and 32/45 (71.1%) of stage 4 CKD subjects receiving
regadenoson and 15/23 (65.2%) receiving placebo (differ-
ence -5.9%; 95% conﬁdence interval -29.4%, 17.6%).
Interestingly, the proportions of subjects with oxygen
saturation \92% at any time during the 2-h continuous
pre-dose monitoring period were also similar between the
treatmentgroups:199/276(72.1%)ofstage3CKDsubjects
receiving regadenoson and 98/142 (69.0%) receiving pla-
cebo(difference-3.1%;95%conﬁdenceinterval-12.4%,
6.2%),and31/45(68.9%)ofstage4CKDsubjectsreceiving
regadenoson and 14/23 (60.9%) receiving placebo (differ-
ence -8.0%; 95% conﬁdence interval -32.1%, 16.1%).
None of the changes in oxygen saturation resulted in any
clinicallymeaningfuladverseeventsrequiringintervention.
Physical examination ﬁndings were unremarkable.
DISCUSSION
A previous Phase 1 study in healthy male volunteers
showed that renal excretion was a major elimination
pathway for regadenoson, with an average of 57%
(range 19%-77%) of a given IV dose being excreted
unchanged in the urine.
22 It was also shown that the
average plasma renal clearance of regadenoson (approx-
imately 450 mL/minute) exceeded the normal GFR,
indicating that active renal tubular secretion plays a role
in the elimination of the drug.
22 A subsequent Phase 1
study investigated the pharmacokinetics and tolerabil-
ity of regadenoson (single IV 0.4 mg bolus) in
subjects (n = 24) with varying degrees of kidney
function (creatinine clearance \30 mL/minute, n = 5;
30-49 mL/minute, n = 6; 50-79 mL/minute, n = 7; 80-
140 mL/minute, n = 6).
12 An inverse correlation was
observed between the severity of CKD and regadenoson
urinary clearance, total clearance, and terminal elimi-
nation half-life. However, plasma concentration-time
curves directly post-dose (when the pharmacodynamic
effect is most important for radiotracer uptake) were
unaffected by creatinine clearance, as evidenced by
similar maximum plasma concentrations and similar
volumes of distribution estimates across the categories.
The number and severity of adverse events were also
comparable among this small sample of subjects. This
study was conducted to further explore the safety and
tolerability of regadenoson among individuals with
decreased renal function.
This randomized controlled trial of regadenoson
versus placebo demonstrated that the safety proﬁle of
regadenoson in individuals with stage 3 or 4 CKD was
similar to the safety proﬁle observed in patients partic-
ipating in previous Phase 3 clinical trials with the
drug.
17,18 For example, a total of 80% of those who
received regadenoson in the pivotal, Phase 3 clinical
trials reported an adverse event
6 compared with 62.6%
in this study. No serious adverse events were reported
from the time of administration of a single IV 0.4 mg
dose of regadenoson or placebo to the follow-up visit,
24-h post-dose. Of the 2 adverse events of clinical
importance that occurred in the regadenoson group, only
1 was considered possibly related to study drug. This
was a 28-minute episode of left hemiparesis beginning
2 minutes after the administration of regadenoson,
which coincided with a period of low oxygen saturation
(documented as 86% at 5 minutes post-dose, the ﬁrst
time it was measured after dosing). This individual had
had sleep apnea and right facial numbness since 2009,
but he was not receiving treatment for either condition at
the time of the study. People with sleep apnea, espe-
cially those not on continuous positive airway pressure
therapy, are susceptible to strokes and transient ischemic
attacks.
23 The adverse event proﬁle of regadenoson in
subjects with stage 3 or 4 CKD was consistent with
previous trials with the drug,
17,18,24 with no unexpected
adverse events being reported. Headache, dyspnea, chest
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the notable side effects that were signiﬁcantly more
common with regadenoson than placebo, as expected.
The frequency of these side effects was comparable to
previously published data from pivotal regadenoson
Phase 3 trials.
17,18 Adverse event proﬁles were also
similar between subjects with stage 3 and 4 CKD for
regadenoson and for placebo (i.e., the types and
frequencies of adverse events with regadenoson [or
placebo] were similar regardless of CKD stage).
Although a slightly higher proportion of subjects with
stage 3 than stage 4 CKD experienced an adverse event,
this difference likely reﬂects the small number of
subjects with stage 4 CKD. With greater numbers of
subjects with stage 4 CKD, the differences would most
likely be less. Using the overall adverse event rates,
comparing the number of subjects in the stage 3 versus
the stage 4 CKD group with adverse events and the
number of subjects without adverse events, the results
are not statistically signiﬁcant (Fisher’s exact test). It is
also not statistically signiﬁcant for placebo-treated
subjects in the stage 3 versus stage 4 CKD groups.
There is also no difference in the safety proﬁle from a
clinically meaningful standpoint. Most adverse events
occurred in the 2 h following regadenoson administra-
tion, consistent with the pharmacodynamic effect and
terminal half-life of the drug.
6,22,25
The proportion of subjects whose HR exceeded
100 bpm was greater with regadenoson than placebo; all
other vital sign criteria were comparable between the 2
treatment groups. The tachycardic effect was noted
despite 55.1% of regadenoson subjects being on beta-
blockers at the time of the study. Two mechanisms appear
to account for the tachycardia induced by regadenoson.
First, peripheral vasodilation following drug administra-
tion leads to a fall in blood pressure, triggering a
baroreﬂex-mediated activation of the sympathetic nervous
system and a subsequent increase in HR.
26 Second,
evidence from animal models suggests that regadenoson
also causes direct sympathoexcitation through stimulation
of arterial chemoreceptors via A2A receptors, such that the
regadenoson-induced tachycardia is dissociated from the
decrease in mean arterial pressure.
26
No clinically important differences were apparent
between the regadenoson and the placebo groups with
regard to changes from baseline in clinical laboratory
ﬁndings or ECG abnormalities following drug adminis-
tration. The changes in these parameters, when observed,
were not clinically meaningful and none required inter-
vention. One subject experienced left hemiparesis, which
was considered possibly related to regadenoson
administration, concurrently with a decrease in oxygen
saturation.
LIMITATIONS
Several limitations should be considered when
evaluating the results of this study. First, of the 504
subjects that were randomized, only 72 (14%) had stage
4 CKD. Thus, the results of this study in this subgroup of
subjects should be interpreted with caution. Second, the
trial did not include subjects with stage 5 CKD (on
dialysis). Third, no pharmacokinetic data were collected
to support the previously published ﬁndings of Gordi
et al,
12 which included only a small number of patients
with impaired renal function. For drugs that are elim-
inated by the kidney (i.e., C30% of the administered
dose eliminated unchanged in the urine), renal impair-
ment often results in a signiﬁcant increase in drug
exposure, manifested as an increase in the area under the
concentration-time curve.
27 In some cases, this necessi-
tates a recommendation for dose adjustment according
to the degree of renal dysfunction.
27 Regadenoson
plasma concentrations display a tri-exponential decline
after administration of an IV bolus dose, with rapid
distribution phases followed by a relatively longer
elimination phase.
22 Any increase in exposure to regad-
enoson in patients with renal impairment would be
expected to occur during the ﬁnal phase of clearance.
However, most adverse events observed with regadeno-
son occur shortly after dosing and resolve within
approximately 15 minutes (except for headache, which
may last for 30 minutes), reﬂecting the timing of the
drug’s pharmacodynamic effect.
6,28,29 Thus, it is unli-
kely that an increase in regadenoson exposure among
patients with renal impairment would affect the adverse
event proﬁle, a speculation supported by the results of
this study.
CONCLUSION
This study demonstrated that regadenoson, an A2A
receptor agonist, has a safety proﬁle in individuals with
stage 3 or 4 CKD that is comparable to the safety proﬁle
in the general patient population, although it should be
noted that only 14% of subjects included had stage 4
CKD. These results indicate that regadenoson is suitable
for use as a coronary vasodilator for pharmacologic
stress MPI in patients with stage 3 or 4 CKD.
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